Tesla and SpaceX CEO Elon Musk clarified that he uses only "a small amount once every other week or something like that" ...

Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...

In terms of the newest collaboration, the health care professionals said they decided that having all the services under one ...

The remaining 20% is their coinsurance. S-ketamine, or esketamine (Spravato), is an FDA-approved nasal spray that doctors and healthcare professionals may prescribe for major depressive disorder ...

Up to 40% of people who suffer from depression are unable to find any relief for their condition. But now, Blessing ...

Discover recent clinical trial failures in depression and explore potential pathways for advancing antidepressant drug ...

J&J has received US FDA approval for Tremfya (guselkumab), to treat moderately to severely active Crohn's disease (CD) in ...

Esketamine, sold under the brand name SPRAVATO® is the FDA-approved nasal spray for adults with treatment-resistant depression. According to the company, it can used alone or “with an oral ...

Johnson & Johnson will stop late-stage studies of its experimental drug to treat major depressive disorder due to a lack of sufficient efficacy, the drug and medical device maker said on Thursday.

The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...